#Bovine-derived #influenza A virus #H5N1 shows efficient #replication in well-differentiated #human #nasal epithelial cells without requiring genetic #adaptation

Nasal drops fight brain tumors noninvasively

Glioblastoma tumors form from brain cells called astrocytes and are the most common kind of brain cancer

Howard G. Smith MD, AM on Instagram: "Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Have Fungal Contamination. This can trigger serious or life-threatening infections in children, in those with weak immune systems individuals, an for anyone with damaged nasal linings. All units sold in the US and in Puerto Ricos are affected. This recall does not affect other Zicam or Orajel products, such as Zicam RapidMelts. Stop using these products immediately. To receive a full refund, visit churchdwightrecall.com or call Church & Dwight’s Consumer Relations team at 800-981-4710. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/church-dwight-co-inc-issues-voluntary-nationwide-recall-zicamr-cold-remedy-nasal-swabs-zicamr-nasal #zicam #nasal #oragel #fungus #infection #recall"

0 likes, 0 comments - drhowardsmithreports on June 17, 2025: "Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Have Fungal Contamination. This can trigger serious or life-threatening infections in children, in those with weak immune systems individuals, an for anyone with damaged nasal linings. All units sold in the US and in Puerto Ricos are affected. This recall does not affect other Zicam or Orajel products, such as Zicam RapidMelts. Stop using these products immediately. To receive a full refund, visit churchdwightrecall.com or call Church & Dwight’s Consumer Relations team at 800-981-4710. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/church-dwight-co-inc-issues-voluntary-nationwide-recall-zicamr-cold-remedy-nasal-swabs-zicamr-nasal #zicam #nasal #oragel #fungus #infection #recall".

Howard G. Smith MD, AM on Instagram: "Spray Away Your Migraines The FDA has just approved a new nasal powder spray called Atzumi that delivers the drug dihydroergotamine, or DHE via a novel nasal spray technology developed by Satsuma Pharmaceuticals. It’s the first and only product to use SMART, which stands for. Simple MucoAdhesive Release Technology. The drug is delivered in a powder with a unique ability to adhere on tissue linings thereby enhancing absorption. The DHE causes cerebral blood vessels to contract, blocks pain transmission, and inhibits inflammatory neurotransmitters all leading to migraine resolution. The Atzumi migraine nasal spray was tested in the 12 month safety and tolerability ASCEND study involving 344 participants. Those using the spray after acute onset of migraine were surveyed at 2, 4, and 24 hours following symptom onset to assess its short and longer-term effects. At 2 hours, 37% were pain-free, 54% denied bothersome symptoms, and two-thirds had headache relief. These stats increased to 86%, 91%, and 94% by 24 hours. Atzumi is FDA-approved for migraine treatment rather than migraine prevention. These preliminary results suggest that this nasal spray may be a powerful tool that can quickly and effectively eradicate migraines. It will also prove to be a welcome alternative for migraine sufferers who cannot tolerate other oral or injection therapies. https://pubmed.ncbi.nlm.nih.gov/39373843/ https://www.medscape.com/viewarticle/fda-okays-dihydroergotamine-nasal-spray-acute-migraine-2025a1000auy #migraine #nasal #powder #mucoadhesive #atzumi"

0 likes, 0 comments - drhowardsmithreports on May 22, 2025: "Spray Away Your Migraines The FDA has just approved a new nasal powder spray called Atzumi that delivers the drug dihydroergotamine, or DHE via a novel nasal spray technology developed by Satsuma Pharmaceuticals. It’s the first and only product to use SMART, which stands for. Simple MucoAdhesive Release Technology. The drug is delivered in a powder with a unique ability to adhere on tissue linings thereby enhancing absorption. The DHE causes cerebral blood vessels to contract, blocks pain transmission, and inhibits inflammatory neurotransmitters all leading to migraine resolution. The Atzumi migraine nasal spray was tested in the 12 month safety and tolerability ASCEND study involving 344 participants. Those using the spray after acute onset of migraine were surveyed at 2, 4, and 24 hours following symptom onset to assess its short and longer-term effects. At 2 hours, 37% were pain-free, 54% denied bothersome symptoms, and two-thirds had headache relief. These stats increased to 86%, 91%, and 94% by 24 hours. Atzumi is FDA-approved for migraine treatment rather than migraine prevention. These preliminary results suggest that this nasal spray may be a powerful tool that can quickly and effectively eradicate migraines. It will also prove to be a welcome alternative for migraine sufferers who cannot tolerate other oral or injection therapies. https://pubmed.ncbi.nlm.nih.gov/39373843/ https://www.medscape.com/viewarticle/fda-okays-dihydroergotamine-nasal-spray-acute-migraine-2025a1000auy #migraine #nasal #powder #mucoadhesive #atzumi".

Variable #DPP4 #expression in multiciliated cells of the #human #nasal #epithelium as a determinant for #MERS-CoV tropism